Treatment for patients with newly diagnosed diffuse large B cell lymphoma

What we are studying

Study participants will receive standard of care therapy (RCHOP) or standard of care therapy plus lenalidomide (R2CHOP)

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • No previous treatment for lymphoma is allowed

What is involved

  • Study treatment is outpatient and given every 21 days

Contact Information

Study Coordinator
Robin Harrelson, RN
Email
rharrels@wakehealth.edu
Phone
336-713-6924

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.